|
Video: What is a Stock Split?
|
|
Enanta Pharmaceuticals is a biotechnology company that engaged in the discovery and development of small molecule drugs for the treatment of viral infections. Co.'s primary wholly-owned research and development programs are in virology, namely respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, hepatitis B virus and human metapneumovirus. Co.'s out-licensed products include two protease inhibitors, which are developed through Co.'s Collaborative Development and License Agreement with AbbVie have been clinically tested, manufactured, and commercialized by AbbVie as part of its combination regimens for hepatitis C virus. According to our ENTA split history records, Enanta Pharmaceuticals has had 0 splits. | |
|
Enanta Pharmaceuticals (ENTA) has 0 splits in our ENTA split history database.
Looking at the ENTA split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Enanta Pharmaceuticals shares, starting with a $10,000 purchase of ENTA, presented on a split-history-adjusted basis factoring in the complete ENTA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/31/2014 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$39.99 |
|
End price/share: |
$16.53 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-58.66% |
|
Average Annual Total Return: |
-8.46% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,132.51 |
|
Years: |
10.00 |
|
|
|
|
|